Mal-PEG2-Val-Cit-PAB-MMAE may be employed in the development of antibody drug conjugates (ADCs). It contains a thiol reactive maleimide group, a protease-sensitive Val-Cit dipeptide, a PABC linker and a MMAE payload. The MMAE is a synthetic antineoplastic agent.
Usually ships within 24 hours.